FFL Flash Alert - Now the main man in Dallas, will the Cowboys QB deliver on Monday night?
FFL Flash Alert - Now the main man in Dallas, will the Cowboys QB deliver on Monday night?
PGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation
The tech giant's business was likely boosted by US sanctions against its Chinese rival Huawei.
Asian stock markets fell on Thursday but not as sharply as Wall Street's rout overnight, while oil bounced off lows and U.S. futures jumped, as Asia's brighter economic outlook offset investor worries about fresh COVID-19 lockdowns in Europe. MSCI's broadest index of Asia-Pacific shares outside Japan <.MIAPJ0000PUS> fell 1%. Japan's Nikkei <.N225> fell 0.8% and drops in Hong Kong <.HSI>, Sydney <.AXJO>, Shanghai <.SSEC> and Seoul <.KS11> were smaller than 1.5%.
The market can be a brutal place -- just ask SAP (SAP). The German software giant’s share price nosedived by 27% this week, its sharpest drop in 12 years, after COVID-19 impacted Q3 results and inflicted cuts on the firm’s full year guidance.SAP reported Q3 revenue of €6.54 billion, missing the estimates by €310 million and indicating a year-over-year drop of 4%. One-time benefits boosted the bottom line as Non-GAAP EPS of €1.70 beat the forecasts by €0.40.Optimism was provided by the pure-cloud category, with revenue increasing by 11% to €1.98 billion. However, most results missed across the board, and operating profit declined by 12%. Looking ahead, SAP toned down its full-year revenue guidance to $32.5 billion, 2% below the company’s previous estimate.RBC analyst Alex Zukin believes SAP’s focus on transitioning to the Cloud “means lower margin targets over the next few years.” However, the analyst believes that in the long run, the efforts “could result in a more robust model.”Expounding on this, the 5-star analyst said, “After a better than expected 2Q, SAP assumed continued recovery. With COVID continuing to weigh heavily, that didn't materialize, particularly at quarter end. With customers telling management they are looking to accelerate their Cloud moves, SAP chose to double down now. A key part of this will be the coming announcement of a simplified bundled commercial package; The result is likely a mix shift away from high margin license and maintenance to subscription, reducing midterm revenue expectations, and 2023 operating margin ambitions by 4-5pp, but could be a growth catalyst down the road.”All in all, Zukin reiterated a Market Perform (i.e. Hold) on the shares yet reduced the price target significantly from $162 to $110. The new figure implies shares will stay range-bound for the foreseeable future. (To watch Zukin’s track record, click here)SAP’s analyst ratings are a mixed bag. Based on 5 Buys and 4 Holds, the stock qualifies with a Moderate Buy consensus rating. Following the sharp decline, the $142.80 average price target suggests possible upside of 32% in the year ahead. (See SAP stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Australia's COVID-19 hotspot state Victoria reported only one new infection on Thursday, a day after it lifted a four month lockdown in the city of Melbourne. Victoria state Premier Daniel Andrews said that while there were three positive cases of COVID-19 detected in the past 24 hours, two may be old infections. "This is another good day," Andrews told reporters in Melbourne.
This year's Dodgers-Rays matchup saw a record low average viewership.
Kelly Curtis, who has managed Pearl Jam since its 1990 formation, has retired. Curtis, 64, stepped away from his role in August but did not make any official announcement at the time, Variety can reveal. Longtime Pearl Jam tour manager Mark “Smitty” Smith has assumed managerial duties for the Seattle-based 2017 Rock and Roll Hall […]
The presidential nominee promised voters he will "let science drive our decisions" about COVID-19 pandemic if elected
Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share. In addition, in lieu of common stock to certain investors, Scholar Rock is offering pre-funded warrants to purchase 2,179,487 shares of its common stock at a purchase price of $38.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. The aggregate gross proceeds to Scholar Rock from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 769,230 shares of common stock at the public offering price per share of the common stock, less the underwriting discounts and commissions. The offering is expected to close on November 2, 2020, subject to the satisfaction of customary closing conditions. All of the shares and pre-funded warrants are being offered by Scholar Rock.
"Puppies probably don't stay in the shelter for more than a couple of days," said Ilsa Jule, the executive director at Family Dog Rescue in San Francisco.
The Europe anti-viral therapies market is expected to reach US$ 21,122. 66 million by 2027 from US$ 11,401. 67 million in 2019; it is estimated to grow at a CAGR of 8. 1% during 2020–2027. The market is growth is primarily attributed to the increasing R&D; expenditures in pharmaceutical companies and rising government support for research activities and clinical trials in Europe.New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Mechanism of Action, and Application, and Country" - https://www.reportlinker.com/p05978841/?utm_source=GNW Additionally, strong pipeline of anti-viral drugs, and growing emphasis on launching anti-viral agents are likely to fuel the growth of the Europe anti-viral therapies market during the forecast period. High cost of drug development is a key factor restraining the growth of the market. Antiviral therapy is one of the most exciting branches of virology. These therapies are based on several strategies—direct-acting antivirals target viral proteins, enzymes, or nucleic acids; passive antibodies neutralize circulating viruses; and several other antivirals target cellular proteins or processes essential for viral replication. Research and development (R&D) is an essential part of any business.Pharmaceutical companies focus on R&D to introduce new drugs with enhanced medical and commercial potential. These companies invest majorly in R&D activities with an aim to deliver high-quality and innovative products in the market. As per the Association of the British Pharmaceutical Industry Pharmaceutical R&D expenditures grew by >11% in the UK in 2001, reaching an estimated US$ 5.23 billion. Johnson & Johnson, and Pfizer are among the top 10 leading R&D investing companies. The UK’s relative stability compared to the rest of Europe as a base for investment to an increase in R&D activity there by the three largest pharmaceutical investors. AstraZeneca, GlaxoSmithKline, and Pfizer collectively signify over 70% of total R&D spending in the UK, while other manufacturers with a significant presence in the country include Merck, Sharp & Dohme, Organon, Eli Lilly, and Novartis. Additionally, the pharma companies in the Germany are highly engaged in R&D activities. Europe has witnessed exponential growth in the count of COVID-19 cases.Spain, Italy, Germany, France, and the UK are among the most affected European countries. Growing research activities to develop treatment against corona virus is likely to favor the growth of the market in this region.In June 2020, the scientists from the University of Oxford tested existing drugs as therapies against this novel virus. Further, the European Commission in July authorized the anti-viral drug Remdesivir for its use in the treatment of COVID-19 patients, making it the first approved drug in the European Union for the treatment. In 2019, the branded drugs segment accounted for a larger share of the Europe antiviral therapies market.The branded antiviral drugs are more trusted than the generic drugs. Further, robust research and development activities, increasing number of drug discoveries, and rising number of patents for drugs are the factors supporting the growth of this segment. A few of the major secondary sources associated with the Europe anti-viral therapies market report are the World Health Organization (WHO), International Trade Administration (ITA), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Health Regulation (IHR), Association of the British Pharmaceutical Industry, and National AIDS Trusts (NAT). Read the full report: https://www.reportlinker.com/p05978841/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
My name is April, and I will be your conference facilitator today for Amgen's Third Quarter 2020 Financial Results Conference Call. You'll recall that Amgen grew revenues by 11% in the first quarter of the year, with the first 10 weeks of performance largely unaffected by the pandemic.
With us on the call today is our CEO, Ignacio Alvarez; our CFO, Carlos Vazquez; and our CRO, Lidio Soriano. Following a strict lockdown between mid-March and late May that helped curtail the initial spread of the pandemic.
GSK earnings call for the period ending September 30, 2020.
Image source: The Motley Fool. National Energy Services Reunited Corp. (NASDAQ: NESR)Q3 2020 Earnings CallOct 28, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the National Energy Services Reunited Q3 2020 Earnings Conference Call.
Out of 1,444 four-year colleges and universities examined, only 7% are testing the entire student population at least weekly for COVID-19. We talked to three Bay Area students who plan to take matters into their own hands before traveling home.
They're warm and durable enough to use through winter — even it in the snow!
The Global Steam Cleaner Market will grow by $ 308.76 mn during 2020-2024
(Bloomberg) -- Hurricane Zeta is walloping New Orleans with the most powerful winds since Katrina devastated the city in 2005, blacking out tens of thousands of homes and businesses, knocking out traffic lights and triggering voluntary evacuations.Zeta made landfall near Cocodrie, Louisiana, with winds of 110 miles (177 kilometers) per hour, before weakening slightly to 100 mph, according to an advisory. The category 2 storm is the fifth hurricane or tropical storm to hit the state this year, the National Hurricane Center said. Never before have so many major storms smashed into Louisiana or the contiguous U.S. in a single season, according to Phil Klotzbach, a hurricane researcher with Colorado State University.While Zeta isn’t as powerful as Katrina, it is running directly over the Crescent City, bringing the harshest winds in 15 years. By moving at a brisk 25 miles an hour, it could pass over quickly enough to spare New Orleans catastrophic flooding even as it claimed its first victim by electrocution on Wednesday. Damages may still total as much as $5 billion.“This is going to be one of the worst hurricanes to hit New Orleans proper since Katrina,” said Jim Rouiller, chief meteorologist at Energy Weather Group LLC.Zeta is the latest in a grim parade of natural disasters to hit the U.S. in recent months as climate change makes weather increasingly extreme. In California, heat waves, drought and violent winds have combined to fuel a rash of wildfires that have burned a record 4.1 acres this year. And along the East and Gulf coasts, a record 11 named storms have hit the U.S.In all, 27 storms have formed across the Atlantic in 2020. So many systems have formed this season that the National Hurricane Center has used up all its official titles and has resorted to the Greek alphabet to designate new ones.The eye of the storm was moving into New Orleans by about 7 p.m. New York time, the city’s emergency response agency said on Twitter. More than 280,000 homes and businesses across Louisiana lost power within hours. The electrical failures knocked out traffic lights, and government officials warned residents to stay off the roads.Zeta becomes only one of six storms to hit the U.S. this late in October and the first hurricane to do so since 1985, said Jeff Masters, a meteorologist with Yale Climate Connection. While Sandy was a powerful storm when it came ashore in New Jersey in 2012, it had lost its hurricane characteristics when it struck land.Rapid IntensificationZeta grew in strength as it moved across the Gulf, and all told this year six storms have rapidly intensified -- short of a record, but indicative of climate change.“There have been a lot of rapidly intensifying storms and that is something we expect to see in a warming climate,” Masters said.Zeta may cause as much as $5 billion in damages and losses, said Chuck Watson, a damage modeler at Enki Research, who raised his estimate from an initial $1 billion as the forecast worsened. The storm’s stronger winds bring more dynamic pressure on everything it hits, and there are simply more targets in the way the closer to New Orleans it gets.While the intensity and number of storms has surpassed the 12 that usually form in an average season, there is no indication things will stop as October ends and November begins.A potential storm could form in the Caribbean Sea within the next week, which would be called Eta. This would be the 28th storm and tie a record with 2005 for the most in a single year.Not Done YetThere might even be more. A global weather pattern called the Madden Julian Oscillation that’s about to exert its influence on the Atlantic may spark a spate of storms. The Atlantic is still warm enough to spin up hurricanes and there are still plenty of tropical waves, the building blocks of hurricanes, emanating from Africa, Masters said.In addition, autumn cold fronts moving off North America often swirl into tropical storms.“I suspect we will see one or two of those this year,” Masters said. “Thirty storms are possible.”(Updates with latest wind speed and casualty in 2nd, 3rd paragraphs.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.